Limosilactobacillus fermentum CECT5716
Limosilactobacillus fermentum CECT5716 (previously classified as Lactobacillus fermentum CECT5716) was originally isolated from human breast milk, an origin that has shaped much of the research into its applications. Human randomized controlled trials include a one-year infant formula supplementation trial and a trial examining its use in breastfeeding women in the context of mastitis prevention. Animal studies have examined this species in the context of gut inflammation, including in high-fat-diet mouse models of obesity-related gut dysbiosis, and in vitro work has characterized its immunomodulatory properties. The strain has been the subject of reviews in pediatric nutrition and is considered relatively well-characterized within the Lactobacillaceae family. These are research topics, not findings; the papers do not establish that this strain treats or prevents any condition.
Where it's been studied Tags come from a conservative keyword scan of each paper's title, abstract, and summary. A tag is research coverage, not measured effect. How we classify this →
Share of this strain's 61 body-system-tagged papers that concern each system. Research coverage, not measured effect.
+3 more systems
Symptoms in the research A tag means the paper's text names the symptom or condition — research coverage, not evidence of benefit. How we classify this →
Share of this strain's 32 symptom-tagged papers that mention each symptom or condition. Research coverage, not evidence of benefit.
Research Study-type filters use AI-classified labels, audited but not guaranteed — check the paper itself before leaning on one. How we classify this →
91 papers reference this strain in the probiotic database.
Discussion
Be the first to comment.
Sign in to join the discussion.
Citations
Selected papers that name this strain.
-
[1]
PMID 42356278 →Bioactive Low-Molecular-Weight Fraction from Limosilactobacillus fermentum CECT5716 Attenuates Intestinal Inflammation and Dysbiosis in DSS-Treated Mice· Nutrients · 2026
-
[2]
PMID 37432320 →Limosilactobacillus fermentum CECT5716: Clinical Potential of a Probiotic Strain Isolated from Human Milk· Nutrients · 2023
-
[3]
PMID 36202884 →Breast microecology improvement using probiotics following needle aspiration in patients with lactational breast abscess: a multi-center randomized double-blind controlled trial· Scientific Reports · 2022
-
[4]
PMID 34208893 →Evaluation of the Effect of Limosilactobacillus fermentum CECT5716 on Gastrointestinal Infections in Infants: A Systematic Review and Meta-Analysis· Microorganisms · 2021
-
[5]
PMID 33801082 →Limosilactobacillus fermentum CECT5716: Mechanisms and Therapeutic Insights· Nutrients · 2021
-
[6]
Source →Interventions to improve and evaluate breastfeeding patterns and outcomes in the first year following birth· The Sydney eScholarship Repository (The University of Sydney) · 2020
-
[7]
PMID 21873895 →Human Milk Probiotic Lactobacillus fermentum CECT5716 Reduces the Incidence of Gastrointestinal and Upper Respiratory Tract Infections in Infants· Journal of Pediatric Gastroenterology and Nutrition · 2011
-
[8]
PMID 20455694 →Treatment of Infectious Mastitis during Lactation: Antibiotics versus Oral Administration of Lactobacilli Isolated from Breast Milk· Clinical Infectious Diseases · 2010